Imaging-based modalities compared for identifying at-risk MASH

Дата публикации: 16-10-2026 18:40:01

FibroScan-aspartate aminotransferase (FAST) demonstrated the highest sensitivity for ruling out at-risk metabolic dysfunction-associated steatohepatitis (MASH), according to a study published in the October issue of the American Journal of Gastroenterology.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Researchers identify high-IgA MASLD subtype linked to liver-related events	0	11.32	09-10-2026
2	MASH Comorbidity Burden and Overall, Waiting List, and Post–Liver Transplant Mortality	0	8.64	05-08-2026
3	Protein discovery reveals potential treatment target for common fatty liver disease	0	9.8	19-10-2026
4	Recommendations developed for preventive care in cirrhosis	0	7.97	16-10-2026
5	Geyserlike OCT Sign in Transthyretin Amyloidosis	0	9.78	01-07-2026
6	Immune Checkpoint Inhibitor–Based Downstaging Therapy for Hepatocellular Carcinoma	0	7.13	01-10-2026
7	Validation of the Semi-Quantitative MRI (SQ-MRI) Score as a Biomarker for Non-Calcific Chronic Pancreatitis in a Multicenter Cohort	0	25.16	18-08-2026
8	Ученые сообщили о пяти подтипах жировой болезни печени	0	7.59	19-10-2026
9	Retinal scans may flag atrial fibrillation four years before diagnosis	0	7.24	15-09-2026
10	FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma	0	13.78	19-10-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 18.34. Источник: medicalxpress.com.